Improvement would require the effort of large and international clinical trials, as for instance the EsPhALL2010 (NCT00287105) trial, which recommended the use of imatinib post-HSCT for Ph+ ALL or the use of FLT3 inhibitors post-HSCT in AML patients [83]. The gene discussed is FLT3; the disease is acute lymphoblastic leukemia.